Amniotics

In accordance with the instruction for the Nomination Committee, which was adopted by the Annual General Meeting on April 15, 2021, the Nomination Committee shall consist of four members, one representative for each of the three largest shareholders on the last banking day in September and the Chairman of the board of directors. The “three largest shareholders” refers to owner-grouped registered shareholders or otherwise known shareholders. In addition, changes in ownership in the company shall be taken into account. Prior to the appointment of the Nomination Committee, such ownership changes have been taken into account, as Amniotics, as of the last banking day in September, was in the process of carrying out a rights issue of units, the outcome of which was not announced until in October 2023. Based on the above, the Nomination Committee for the Annual General Meeting 2024 has been appointed and consists of:

• Andreas Herbst, representing LSCS Invest AB;
• Marcus Larsson, representing Deflexum AB and own holdings;
• Arne Andersson, representing own holdings; and
• Peter Buhl Jensen, Chairman of the board of directors.

The Nomination Committee submits proposals to the Annual General Meeting regarding, among other things, the composition of the board of directors, remuneration to the board of directors, election of auditors and remuneration to the auditor.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee no later than March 1, 2024. Proposals may be sent via e-mail to: agm@amniotics.com or by regular mail to: Amniotics AB (publ), Attn: Valberedningen, Scheelevägen 2, 223 63 Lund, Sweden.

For more information, contact:

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

The information was submitted for publication, through the agency of the contact person set out above, on December 21, 2023.

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking. Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies. Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.